The 3C Study: Alemtuzumab may reduce acute rejection following kidney transplant
1. Alemtuzumab induction treatment significantly reduced events of biopsy-proven acute rejection (BPAR) when compared with standard basiliximab-based therapy (BBT). 2. ...